Infliximab Treatment in Resistant Pyoderma Gangrenosum: A Case Report.
Pyoderma gangrenosum (PG) is an uncommon neutrophilic dermatosis consisting of nodules and pustules that ulcerate. Pyoderma gangrenosum is associated with autoimmune disorders such as inflammatory bowel disease, spondyloarthritis, and rheumatoid arthritis. In mild disease, therapy consists of local...
| Publicado en: | Turkish Journal of Physical Medicine & Rehabilitation / Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi Vol. 58; no. 4; pp. 332 - 335 |
|---|---|
| Autores principales: | , , , |
| Formato: | case study pictorial tables/charts Journal Article |
| Publicado: |
Turkish Society of Physical Medicine & Rehabilitation
Dec2012
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | Pyoderma gangrenosum (PG) is an uncommon neutrophilic dermatosis consisting of nodules and pustules that ulcerate. Pyoderma gangrenosum is associated with autoimmune disorders such as inflammatory bowel disease, spondyloarthritis, and rheumatoid arthritis. In mild disease, therapy consists of local wound care and topical or intralesional corticosteroids. For more severe disease, systemic agents are necessary. Herein, we present the case of a patient with steroid resistant pyederma gangrenosum associated with ulcerative colitis and ankylosing spondylitis who responded well to infliximab, a tumor necrosis factor blocker. Biological agents (anti-TNF) may be alternative treatment options in patients with resistant PG. |
|---|